|1.||Klose, Uwe: 1 article (04/2012)|
|2.||Nägele, Thomas: 1 article (04/2012)|
|3.||Schwentner, Christian: 1 article (04/2012)|
|4.||Heckl, Stefan: 1 article (04/2012)|
|5.||Horger, Marius: 1 article (04/2012)|
|6.||Deeg, Martin: 1 article (04/2012)|
|7.||Echner, Hartmut: 1 article (04/2012)|
|8.||Kalbacher, Hubert: 1 article (04/2012)|
|9.||Sheikh, Sumbla: 1 article (04/2012)|
|10.||Sturzu, Alexander: 1 article (04/2012)|
05/01/1991 - "Hormonal changes associated with pancreatitis were also significantly altered by CR 1409 administration. "
05/01/1991 - "In a separate group, CR 1409 administration was begun 24 hours following onset of pancreatitis. "
11/01/1986 - "These results, showing a high protective effect of CR 1409 on different models of acute pancreatitis, suggest an important role of CCK in the pathogenesis of pancreatitis."
05/01/1991 - "When administered 24 hours following onset of pancreatitis, CR 1409 was not effective in altering the pancreatitis produced by bile duct ligation. "
08/01/1989 - "CR-1409 completely abolished the adverse effects of hydrocortisone on pancreatitis. "
06/01/1990 - "Moreover, our results on gallbladders from gallstone patients show that lorglumide is a highly effective antagonist of CCK-induced contractions despite the presence of chronic cholecystitis. "
06/01/1990 - "The effect of a novel CCK-antagonist (lorglumide, CR 1409) was evaluated by "in vitro" tensiometric studies on 16 human (gallstone patients) and 12 guinea pig gallbladder smooth muscle strips. "
|4.||Pancreatic Neoplasms (Pancreatic Cancer)
08/01/2010 - "Effects of lorglumide on growth and invasion of human pancreatic cancer cell line Mia PaCa-2 in vitro through the cholecystokinin-cholecystokinin-1 receptor pathway."
05/01/1989 - "It is concluded that (a) cholecystokinin plays a significant role in camostate-stimulated growth of acidophilic putative preneoplastic foci in rat pancreas and (b) CR-1409 inhibits growth of putative preneoplastic foci induced in rat pancreas by azaserine and hence may be of potential value for the treatment of pancreatic cancer in humans."
11/01/1997 - "Our results suggest that a local decrease in pH could play an important role during inflammation, while antagonism of endogenous compensatory systems would explain the reversal of tolerance induced by lorglumide or MK-801."
05/01/1991 - "CR 1409, administered at the onset of pancreatitis, significantly decreased amylase concentrations, gland weight, and inflammation, when compared to control values. "
11/01/1997 - "1. The aim of investigation was to establish and compare the reversibility of tolerance to the antitransit effects of morphine by three different procedures: (a) acute inflammation of the gut, (b) lorglumide a cholecystokininA (CCKA) receptor antagonist, or (c) MK-801, an N-methyl-D-aspartate (NMDA) receptor ion channel blocker. "
|2.||Cholecystokinin Receptors (Cholecystokinin Receptor)
|8.||Dizocilpine Maleate (Dizocilpine)